ArticleNucleic acids research2013
Receptor-mediated delivery of engineered nucleases for genome modification.
Article in Nucleic acids research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- The Development and Expansion of in vivo Germline Editing Technologies in Arthropods: Receptor-Mediated Ovary Transduction of Cargo (ReMOT Control) and Beyond.Integrative and comparative biology · 2023Review
- Engineering of fluorescent or photoactive Trojan probes for detection and eradication of β-Amyloids.Drug delivery · 2020Article
- Protein Delivery of Cell-Penetrating Zinc-Finger Activators Stimulates Latent HIV-1-Infected Cells.Molecular therapy. Methods & clinical development · 2020Article
- Genome editing in wheat microspores and haploid embryos mediated by delivery of ZFN proteins and cell-penetrating peptide complexes.Plant biotechnology journal · 2020Article
- A ligand-based system for receptor-specific delivery of proteins.Scientific reports · 2019Article
- Targeted delivery of CRISPR-Cas9 ribonucleoprotein into arthropod ovaries for heritable germline gene editing.Nature communications · 2018Article
- Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing.Journal of the American Chemical Society · 2018Article
- Cell-penetrating peptides and their utility in genome function modifications (Review).International journal of molecular medicine · 2017Review
- Efficient Recreation of t(11;22) EWSR1-FLI1Stem cell reports · 2017Article
- Multistage vector (MSV) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Controlled delivery of β-globin-targeting TALENs and CRISPR/Cas9 into mammalian cells for genome editing using microinjection.Scientific reports · 2015Article
- Efficient delivery of nuclease proteins for genome editing in human stem cells and primary cells.Nature protocols · 2015Article
- Enabling functional genomics with genome engineering.Genome research · 2015Review
- Recent developments and clinical studies utilizing engineered zinc finger nuclease technology.Cellular and molecular life sciences : CMLS · 2015Review
- Improved cell-penetrating zinc-finger nuclease proteins for precision genome engineering.Molecular therapy. Nucleic acids · 2015Article
- New type of BACE1 siRNA delivery to cells.Medical science monitor : international medical journal of experimental and clinical research · 2014Article
- Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies.Nature reviews. Drug discovery · 2014Review
- Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression.Methods (San Diego, Calif.) · 2014Article
- A guide to genome engineering with programmable nucleases.Nature reviews. Genetics · 2014Review
- Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases.eLife · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
Engineered nucleases, which incise the genome at predetermined sites, have a number of laboratory and clinical applications. There is, however, a need for better methods for controlled intracellular delivery of nucleases. Here, we demonstrate a method for ligand-mediated delivery of zinc finger nucleases (ZFN) proteins using transferrin receptor-mediated endocytosis. Uptake is rapid and efficient in established mammalian cell lines and in primary cells, including mouse and human hematopoietic stem-progenitor cell populations. In contrast to cDNA expression, ZFN protein levels decline rapidly following internalization, affording better temporal control of nuclease activity. We show that transferrin-mediated ZFN uptake leads to site-specific in situ cleavage of the target locus. Additionally, despite the much shorter duration of ZFN activity, the efficiency of gene correction approaches that seen with cDNA-mediated expression. The approach is flexible and general, with the potential for extension to other targeting ligands and nuclease architectures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.